Who are pr Sandoz Tamsulosin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oxymetazoline 0.05% w/v, Fexofenadine HCl + Pseudoephedrine HCl, Pseudoephedrine/Paracetamol, Bupivacaine/epinephrine/dexamethasone, Phenylephrine-ketorolac, Levobupivacaine with epinephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pr-sandoz-tamsulosin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-21 · How we verify

pr Sandoz Tamsulosin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

pr Sandoz Tamsulosin (pr Sandoz Tamsulosin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic receptor antagonist. Area: Urology.

phase 3 Alpha-1 adrenergic receptor antagonist Alpha-1 adrenergic receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

pr Sandoz Tamsulosin (pr Sandoz Tamsulosin) — CHU de Quebec-Universite Laval. Tamsulosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscles in the prostate and bladder neck, improving urine flow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
pr Sandoz Tamsulosin TARGET	pr Sandoz Tamsulosin	CHU de Quebec-Universite Laval	phase 3	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Oxymetazoline 0.05% w/v	Oxymetazoline 0.05% w/v	Brian J Lipworth	marketed	Alpha-1 adrenergic agonist (nasal decongestant)	Alpha-1 adrenergic receptor
Fexofenadine HCl + Pseudoephedrine HCl	Fexofenadine HCl + Pseudoephedrine HCl	Dr. Reddy's Laboratories Limited	marketed	Antihistamine + decongestant combination	H1 receptor (fexofenadine); alpha-1 adrenergic receptor (pseudoephedrine)
Pseudoephedrine/Paracetamol	Pseudoephedrine/Paracetamol	McNeil AB	marketed	Decongestant/analgesic combination	Alpha-1 adrenergic receptor (pseudoephedrine); COX inhibition (paracetamol)
Bupivacaine/epinephrine/dexamethasone	Bupivacaine/epinephrine/dexamethasone	Cedars-Sinai Medical Center	marketed	Local anesthetic combination	Voltage-gated sodium channels (bupivacaine); alpha-1 adrenergic receptors (epinephrine); glucocorticoid receptor (dexamethasone)
Phenylephrine-ketorolac	Phenylephrine-ketorolac	Milton S. Hershey Medical Center	marketed	Combination sympathomimetic and NSAID	Alpha-1 adrenergic receptor (phenylephrine); COX-1/COX-2 (ketorolac)
Levobupivacaine with epinephrine	Levobupivacaine with epinephrine	Pontificia Universidad Catolica de Chile	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic receptor antagonist class)

Brian J Lipworth · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 drug in this class
Hospital Authority, Hong Kong · 1 drug in this class
Japan Heart Foundation · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
San Francisco Veterans Affairs Medical Center · 1 drug in this class
Sanofi · 1 drug in this class
Shanghai Huilun Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pr Sandoz Tamsulosin — Competitive Intelligence Brief. https://druglandscape.com/ci/pr-sandoz-tamsulosin. Accessed 2026-05-21.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab